Cargando…
Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83
CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been widely used as a marker for mature DCs. Recently, we reported the recombinant expression of the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble form of CD83, allogeneic as wel...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211980/ https://www.ncbi.nlm.nih.gov/pubmed/15289503 http://dx.doi.org/10.1084/jem.20030973 |
_version_ | 1782148596653621248 |
---|---|
author | Zinser, Elisabeth Lechmann, Matthias Golka, Antje Lutz, Manfred B. Steinkasserer, Alexander |
author_facet | Zinser, Elisabeth Lechmann, Matthias Golka, Antje Lutz, Manfred B. Steinkasserer, Alexander |
author_sort | Zinser, Elisabeth |
collection | PubMed |
description | CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been widely used as a marker for mature DCs. Recently, we reported the recombinant expression of the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble form of CD83, allogeneic as well as specific cytotoxic T lymphocyte proliferation could be blocked in vitro. Here we report the functional analysis of soluble CD83 in vivo, using murine experimental autoimmune encephalomyelitis (EAE) as a model. Strikingly, only three injections of soluble CD83 prevented the paralysis associated with EAE almost completely. In addition, even when the EAE was induced a second time, CD83-treated mice were protected, indicating a long-lasting suppressive effect. Furthermore, soluble CD83 strongly reduced the paralysis in different therapeutic settings. Most important, even when the treatment was delayed until the disease symptoms were fully established, soluble CD83 clearly reduced the paralyses. In addition, also when EAE was induced a second time, soluble CD83-treated animals showed reduced disease symptoms. Finally, hCD83ext treatment almost completely reduced leukocyte infiltration in the brain and in the spinal cord. In summary, this work strongly supports an immunosuppressive role of soluble CD83, thereby indicating its therapeutic potential in the regulation of immune disorders in vivo. |
format | Text |
id | pubmed-2211980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-22119802008-03-11 Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 Zinser, Elisabeth Lechmann, Matthias Golka, Antje Lutz, Manfred B. Steinkasserer, Alexander J Exp Med Article CD83 is up-regulated on the surface of dendritic cells (DCs) during maturation and has been widely used as a marker for mature DCs. Recently, we reported the recombinant expression of the extracellular immunoglobulin domain of human CD83 (hCD83ext). Using this soluble form of CD83, allogeneic as well as specific cytotoxic T lymphocyte proliferation could be blocked in vitro. Here we report the functional analysis of soluble CD83 in vivo, using murine experimental autoimmune encephalomyelitis (EAE) as a model. Strikingly, only three injections of soluble CD83 prevented the paralysis associated with EAE almost completely. In addition, even when the EAE was induced a second time, CD83-treated mice were protected, indicating a long-lasting suppressive effect. Furthermore, soluble CD83 strongly reduced the paralysis in different therapeutic settings. Most important, even when the treatment was delayed until the disease symptoms were fully established, soluble CD83 clearly reduced the paralyses. In addition, also when EAE was induced a second time, soluble CD83-treated animals showed reduced disease symptoms. Finally, hCD83ext treatment almost completely reduced leukocyte infiltration in the brain and in the spinal cord. In summary, this work strongly supports an immunosuppressive role of soluble CD83, thereby indicating its therapeutic potential in the regulation of immune disorders in vivo. The Rockefeller University Press 2004-08-02 /pmc/articles/PMC2211980/ /pubmed/15289503 http://dx.doi.org/10.1084/jem.20030973 Text en Copyright © 2004, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Zinser, Elisabeth Lechmann, Matthias Golka, Antje Lutz, Manfred B. Steinkasserer, Alexander Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 |
title | Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 |
title_full | Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 |
title_fullStr | Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 |
title_full_unstemmed | Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 |
title_short | Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83 |
title_sort | prevention and treatment of experimental autoimmune encephalomyelitis by soluble cd83 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211980/ https://www.ncbi.nlm.nih.gov/pubmed/15289503 http://dx.doi.org/10.1084/jem.20030973 |
work_keys_str_mv | AT zinserelisabeth preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83 AT lechmannmatthias preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83 AT golkaantje preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83 AT lutzmanfredb preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83 AT steinkassereralexander preventionandtreatmentofexperimentalautoimmuneencephalomyelitisbysolublecd83 |